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Abstract
Objective—To estimate the effects of gestational age and other maternal factors on immunologic
responses to influenza vaccination.
Methods—Antepartum and postpartum women receiving influenza vaccination as part of routine
clinical care were enrolled through four consecutive vaccination seasons (starting October 2006
through January 2010) Immunologic responses to trivalent inactivated influenza vaccine (TIV)
and monovalent H1N1 were assessed, as well as factors influencing vaccine responsiveness.
Serum samples were obtained at baseline and 4-8 weeks postvaccination.
Results—Two hundred thirty-nine participants were included in the current analysis.
Seroconversion rates to TIV vaccine strains were lowest in the first trimester (54.8%) and
immediate postpartum (54.8%), and were highest in the late third trimester (69.6%) and late
postpartum (69.4%); these differences were not statistically significant (p=0.23). In a
multivariable model, higher baseline antibody levels (p<.001)and prior year flu vaccination
(p=0.03) were both significantly associated with reduced odds of seroconversion. Overall, results
were consistent when comparing TIV and monovalent pandemic H1N1 responses. Although there
was overall no significant association between gestational age at vaccination (p=0.23) or
prepregnancy BMI (p=0.16), we observed somewhat lower rates of seroconversion for women
vaccinated in the first trimester and for obese women.
Conclusions—Adequate immunologic responses to inactivated influenza vaccines were
demonstrated during pregnancy and the postpartum period. No diminution of immunogenicity was
observed in the third trimester a time of increased clinical vulnerability to influenza.
Introduction
Recent global reports of pregnant women, especially in the third trimester, being
disproportionately affected by 2009 A/H1N1 [1-6] are consistent with reports from past
influenza pandemics and support the decade-long public health recommendation to routinely
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immunize pregnant women with trivalent inactivated influenza vaccine (TIV) in order to
protect both women and their infants.[7] Despite these recommendations, vaccination rates,
although recently improved [8,9], remain suboptimal and there have been surprisingly few
reports of vaccine immunogenicity among pregnant women.[10-15] We report immunologic
results from our influenza vaccine cohort study which enrolled pregnant and post-partum
women who had received influenza vaccine as part of their routine standard of care.
Material and Methods
Study design
This study was part of the Mount Sinai Viral Immunity in Pregnancy (VIP) project which
was funded by a NIH-NIAID contract (Immune Responses to Virus Infections During
Pregnancy; Contact No. HHSN266200500028C). The project had two different cohort
studies whose overarching aim was to characterize the immunologic adaptations which
occur as pregnancy progresses. The vaccination cohort study enrolled antepartum and
postpartum women in order to assess factors influencing the immunologic responses to TIV
and to evaluate the spread of influenza-like illness among household members. The study
design involved a baseline visit with blood draw, a post-vaccination visit with blood draw,
and monthly contact visits until the end of flu season (April each year).
The study and all modifications were approved by the Mount Sinai School of Medicine
(MSSM) IRB (MSSM # 05-0054) and study recruitment started in the 2006/2007 influenza
vaccine season and continued through consecutive influenza vaccine seasons. Consistent
with ACIP recommendations, during year 4, we modified our protocol in order to include
women receiving either or both of the two different recommended influenza vaccinations –
the monovalent inactivated vaccine against the circulating pandemic 2009 H1N1 as well as
the standard seasonal 2009/2010 TIV.[8, 16] Patients receiving care at either one of two on-
campus practice sites (the faculty practice or the resident-teaching practice) who were
receiving TIV for clinical indications were eligible for study participation. There were no
exclusions based on maternal co-morbid medical conditions. Subjects were enrolled
throughout pregnancy and at two times post-delivery (either within 72 hours of delivery
while an inpatient and again at approximately 6 weeks post-partum). Serum samples were
obtained pre-vaccination or the day of vaccination and again at 4-8 weeks post-vaccination.
The specimen biorepository was linked to comprehensive maternal data (age, weight, co-
morbid medical conditions, concomitant medications/vaccinations, obstetrical history,
allergies, asthma/atopy, depression/stress assessments, influenza vaccination history,
alcohol/drug use, and smoking/second-hand smoke exposures), pregnancy outcome data,
and information about the spread of influenza-like illness among pregnant women and their
household members.
Assessment of Immunogenicity
Immunologic responses to influenza A were assessed by standard hemagglutination
inhibition (HI) methods. HI titer was determined by the ability of serially diluted RDE
treated serum to inhibit hemagglutination of chicken (H1 strains) or turkey (H3 strains) red
blood cells in round bottom 96 well plates. Viruses used were either pseudotyped (6:2
recombinants) to match vaccine strains (Wisconsin/67/2005, Brisbane 10/2007, Brisbane
59/2007) or wild-type vaccine strains (New Caledonia/20/99, Solomon Islands/03/2006).
Appropriate responses were assessed for both H1N1 and H3N2 strains of each year;
additionally, response to California 04/2009 was assessed for subjects who received the
vaccine for the circulating pandemic H1N1 in 2009-2010.
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Adequacy of serologic responses (seroconversion and seroprotection) were assessed using
the criteria adopted by regulatory agencies to support influenza vaccine licensure.[17]
Seroconversion rates were defined as the proportion of subjects with a ≥ 4-fold increase in
reciprocal HI antibody titer at post-vaccination visit versus pre-vaccination, or a reciprocal
HI titer of ≥ 40 from a starting value <10. Seroconversion rates has been accepted as a
surrogate for clinical vaccine efficacy since studies have demonstrated a strong correlation
between a fourfold rise in serum HI antibody titer and disease protection. By convention,
seroprotection rates were defined as the proportion of participants with HI titers ≥ 1:40.
Geometric means of reciprocal HI titers were calculated for baseline and post-vaccination
samples, and the geometric mean fold-rises (geometric mean of the within-subject fold
increases from pre-and post—vaccination) were also calculated. In addition to HI titers,
immunostaining was performed to determine subtype of IgG antibody response for the
pandemic H1N1 in the 2009/2010 cohort. Briefly, Madin-Darby canine kidney epithelial
cells were infected with California 04/2009 pseudotyped virus at MOI = 5, and then cultured
for 18-24 hrs on 96 well flat bottom plates. Cells, which now express viral proteins HA/NA
were fixed before incubation with serial dilutions of patient serum. A peroxidase-conjugated
secondary antibody that is specific against total IgG, IgG1, IgG3 or IgG4 was used to
identify IgG antibody sub-types.
Statistical Methods
We calculated descriptive statistics, including geometric mean titers, seroconversion rates by
timing of vaccination during gestation, and seroprotection rates according to vaccine strains
and patient characteristics, by vaccine year and overall. For the geometric means, a titer of
less than 10 was interpreted as 5.
We constructed a multivariable adjusted model for seroconversion, starting with a large pool
of variables of interest and then reducing the number of variables using a backward
elimination, ending with those that were statistically significant given the other terms in the
model, or of primary clinical interest. Predictors of seroconversion tested included both
vaccine-related characteristics as well as maternal characteristics. The vaccine- related
variables included: (i) nine combinations of year of administration and strain (see Figure 1),
(ii) baseline HI titer values stratified into 0-20, 40, and 80 and above, and (iii) whether the
woman had a vaccine in the previous year. The maternal characteristics included in the final
model were (i) age (stratified into less than 23, 23-29, and over 30), (ii) obesity (BMI > or =
30 kg/m2), and (iii) education (<high school, high school degree, > high school). Statistical
models accounted for the fact that women had multiple vaccines administered at the same
time (e.g. multiple strains in the inactivated seasonal vaccine and, in year 4, an additional
monovalent H1N1 vaccine) by using generalized linear models as implemented in proc
genmod of SAS version 9.2. We started out by fitting an unstructured 3 by 3 correlation
matrix in which it was assumed that there was a common correlation between any two
vaccine strains administered at the same time, but another correlation between the pandemic
vaccine and each of the two seasonal Brisbane vaccines in year 4. The resulting pattern
indicated, as expected, a positive correlation between the strains administered at the same
time, but based on small sample sizes, we noted a slightly negative correlation between the
pandemic and seasonal vaccine. To assure that the results were not unduly influenced by this
implausible negative correlation between the pandemic and seasonal vaccines, for the final
model, we set these correlations to zero.
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Characteristics of study volunteers
Two hundred and eighty one subjects were enrolled and 245 completed both baseline and
post-vaccination study visits and also had serial specimens available. Those that did not
have a post-vaccination specimen did not differ from the study population in any of the
dimensions summarized in Table 1 (data not shown). In addition, 6 HIV-infected pregnant
subjects were eliminated from the current analysis. The description of the 239 subjects is
summarized in Table 1. Each year, the goal was to complete enrollment prior to the onset of
the peak clinical flu season. In fact, most subjects were vaccinated by the end of November
(Year 1: 89.2%; Year 2: 84.3%; Year 3: 93.0%; Year 4 seasonal: 92.3%; Year 4 H1N1:
66.7%). In total, only 8 subjects reported a possible influenza-like illness (defined as a
febrile illness with either cough or sore throat) at the time of the post-vaccination blood
draw and only 1 of these cases was confirmed by a health-care provider.
Gestational Age Effects – Geometric Mean Titers and Seroconversion Rates
Geometric mean titers pre and post vaccination are presented in Table 2, according to
vaccination year, strain, and timing of vaccination; this table provides descriptive
information without formal statistical testing. Averaged over all strains, geometric mean
titers were higher post versus pre-vaccination regardless of the gestation time period when a
woman was vaccinated. Vaccination in the late postpartum and late third trimester resulted
in the largest post versus pre vaccination titer ratios. During our study period, three viral
strains appeared in two successive flu seasons: Wisconsin H3N2 2006/2007 & 2007/2008,
Brisbane H3N2 2008/2009 & 2009/2010, and Brisbane H1N1 2008/2009 & 2009/2010.
There were no notable differences in geometric mean titers post-vaccination according to
timing or year of vaccination for these repeating strains. The effect of timing of vaccination
on seroconversion is presented in Table 3, which summarizes for each pregnancy time
period the number of women, the average seroconversion rates, and the odds ratio based on
a generalized linear model adjusting for the other terms in the model; data is summarized
separately for all TIV strains combined and for monovalent pandemic H1N1. Averaged over
all strains, the crude rate of seroconversion was lowest in the first trimester (54.8%) and
immediate postpartum (54.8%), and highest in the late third trimester (69.6%) and late
postpartum (69.4%). The low rate of seroconversion in trimester 1 was even more dramatic
for pandemic H1N1 (28.6%). However, this was based on a very small number of subjects.
There were no statistically significant differences in odds of seroconversion according to
time of vaccination (p=0.23).
Multivariable Model – Maternal Predictor of Seroconversion
Relations between immunological and patient characteristics and odds of seroconversion are
presented in Table 4. Baseline antibody titer was strongly related to odds of seroconversion
(p<.001), with the odds of seroconversion falling dramatically with increasing baseline
antibody level. Women who received an influenza vaccination in the previous year had
significantly (p = 0.03) lower odds of seroconversion than those who did not.
Seroconversion rates also varied significantly (p<.001) among the nine vaccine strains
administered during our study period; 2006/7 A Wisconsin had the lowest seroconversion
rates (37%), the 2007/8 Solomon Islands the highest seroconversion rates (78%), and all the
others were in the narrow range 56%-65%. There were no other significant predictors of
seroconversion among the factors examined. As noted previously, differences between
trimesters were not significant (p=.23). In the multivariable adjusted model, maternal
obesity did not reach statistical significance (p=.16); however, obese women (OR = 0.68,
95% CI 0.41, 1.14) had slightly though non-significantly lower odds of seroconversion.
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Seroprotection rates (pre and post-vaccination titers > 1:40) are summarized in Figures 1 &
2; these figures provide descriptive information without formal statistical testing. Higher
baseline (pre-vaccination) seroprotection rates were observed when the same antigen was
utilized in consecutive years. Overall, for H3N2 strains, the seropotection rates post-
vaccination varied from 65% to 95%. Overall for H1N1 strains, the seroprotection rates
post-vaccination varied from 75% to 98%.
IgG Antibody Class Switching
Only 16% of the subjects receiving the monovalent H1N1 vaccine had background levels of
antibody to the pandemic H1N1 strain allowing us to measure IgG antibody class without
interference from pre-existing antibodies. Peroxidase-conjugated secondary antibodies
specific for total IgG, IgG1, IgG3 or IgG4 were used to evaluate immunoglobulin class
switching. Immunostaining is more sensitive than the HI method to detect antibody
responses, and some subjects with negative vaccine responses by HI assay showed clearly
detectable staining post vaccination (data not shown). The results (data not shown)
demonstrated an overwhelming IgG1 response to the vaccine at all vaccination time points
assessed (both antepartum and post-partum). No change in IgG subtype preference was
observed at any time point.
Discussion
We assessed seroconversion rates to TIV through four consecutive flu vaccination seasons
(starting October 2006 through January 2010) as well as to the pandemic 2009 monovalent
H1N1 vaccine and observed rates generally similar to what has been reported among non-
pregnant adults.[17] Pregnant women demonstrated adequate immunologic responses to
inactivated influenza vaccines throughout pregnancy and post-partum. When comparing
seroconversion rates in the different gestational time periods to post-partum rates, the
highest vaccine response rates were observed in the late third trimester (≥ 34 weeks of
gestation) and the lowest response rates were observed in the first trimester (<13 weeks of
gestation) and in the immediate post-partum period (within 72 hours of delivery); however,
these differences were not statistically significant. It is unlikely that any of the observed
antibody responses were confounded by exposure to wild-type circulating virus since almost
all subjects were vaccinated prior to the onset of peak flu season and only 8 subjects
reported a possible influenza like illness at the time of their post-vaccination visit.
Our multivariable model (Table 4) examined both maternal and vaccine characteristics as
potential predictors of seroconversion. Only baseline antibody titer and prior year
vaccination were strongly related to odds of seroconversion. Seroconversion rates also
varied significantly among the nine vaccine strains administered during our study period.
Women over 30 and obese women were observed to have non-significant but lower odds of
seroconversion. Obesity, an increasing prevalent global health problem had emerged as a
probable independent risk factor for Pandemic 2009 H1N1 influenza disease severity.[18]
Obesity has been linked to diminished hepatitis vaccine responsiveness [19] possibly
mediated by immunologic alterations related to adipocyte dysfunction [20], or alternatively
due to improper vaccination technique.[21] We utilized influenza vaccine as our model
because of its routine use during pregnancy. However, it is not an ideal model to study
primary immunologic responses because of the likelihood of significant past exposure to the
vaccine antigens and/or related strains either from prior vaccinations or from prior wild-type
infections. Neutralizing antibodies from previous exposures may block access to B cells or
deliver suppressive signals. In fact, in our cohort, a high level of circulating baseline
antibodies was the strongest predictor of diminished vaccine responsiveness.
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Our study has focused on the third trimester of pregnancy as this has been recognized as a
time of immunologic vulnerability. Suppression of T cell activation has been suggested to be
the basis of increased disease susceptibility and/or increased disease severity to certain
infections including Listeria monocytogenes [22], Plasmodium falciparum [23], Varicella
zoster [24], seasonal influenza[7] and most recently the novel H1N1 influenza.[1-6]
Alterations in B cell function have been less well-studied during pregnancy; however,
significant suppression of B cell lymphopoiesis has been reported[25] and steroid hormones
have been implicated in changes of B cell function[26] including possible changes in isotype
switching.[27]
The availability of subjects who received the monovalent H1N1 vaccine afforded us the
unique opportunity to measure vaccine responses in a naïve population without background
antibody interference. Although we enrolled only a very small number of first trimester
H1N1 vaccinees, our data suggests the possibility of a diminished first trimester immune
response which warrants further investigation. Despite the existing clinical
recommendations for influenza vaccination throughout gestation [7], women in the first
trimester continue to be excluded from participation in clinical trials of pregnancy-related
influenza vaccine immunogenicity.[14] Among our H1N1 vaccinees we were also able to
assess IgG class switching. Immunoglobulin class switching is strongly influenced by the
cytokine milieu[28] which changes during pregnancy in a predictable fashion.[29] Th1
cytokines IFNγ and IL12 drive a switch to the IgG1 subtype while Th2 cytokines such as
IL4 direct a switch to IgG2 and IgG4. As pregnancy progressed, if we had observed a shift
away from IgG1 to other subtypes, this would have provided indirect support for a shift
from Th1 to Th2 dominance which has been posited to occur. In addition, transport across
the placenta varies by class – (IgG1>IgG4>IgG3>IgG2) and a switch in IgG class could
potentially influence the protection afforded to the newborn.[30] We did not observe a
change in IgG subtype; at all gestational time points tested, IgG1 overwhelmingly
dominated the response.
In summary, our observational cohort study provides practical guidance to clinicians faced
with the need to counsel pregnant and post-partum patients about the benefits of influenza
vaccination and also further elucidates our understanding of the immunologic alterations
which characterize normal gestation. Vaccine responsiveness to inactivated influenza
vaccines antigens was demonstrated throughout gestation with no diminution seen in the
third trimester, a time strongly associated with increased influenza-related morbidity and
mortality. Although our study was not designed and powered to identify the ideal time to
vaccinate women during pregnancy, our data does suggest the possibility of lower
seroconversion rates in the first trimester as well as in the immediate post-partum period. In
addition, obesity may also be associated with lower seroconversion rates. Future studies
specifically designed to assess the gestational age effect on vaccine responsiveness and
among obese pregnant women are warranted by our observations and would help to refine
influenza and other vaccination recommendations for pregnant and post-partum women.
Acknowledgments
The authors thank Heidi Hess, PA, and Rachel Gerber, PA, for recruitment and retention of study participants, as
well as Bhakti Rawal and Sharon Czelusniak for technical support in the laboratory.
Supported by the National Institute of Allergies and Infectious Diseases - Division of Allergy, Immunology and
Transplantation of the National Institutes of Health [grant number N01-AI-50028].
Sperling et al. Page 6














1. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during
pregnancy in the USA. Lancet. 2009; 374(9688):451–8. [PubMed: 19643469]
2. The ANZIC Influenza Investigators Australasian Maternity Outcomes Surveillance System. Critical
illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort
study. BMJ. 2010; 340:c1279. [PubMed: 20299694]
3. Louie JK, Acosta M, Jamieson DJ, Honein MA. for the California Pandemic (H1N1) Working
Goup. Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California. N Engl J
Med. 2010; 362(1):27–35. [PubMed: 20032319]
4. Fine AM, Dentinger C, Johnson T, et al. 2009 Pandemic Influenza A (H1N1) in Pregnant Women
Requiring Intensive Care - New York City, 2009. MMWR. 2010; 59(11):321–6. [PubMed:
20339343]
5. Siston AM, Rasmmussen SA, Honein MA, et al. Pandemic 2009 Influenza A(H1N1) Virus Illness
Among Pregnant Women in the United States. JAMA. 2010; 303(15):1517–25. [PubMed:
20407061]
6. Mosby LG, Rasmussen SA, Jamieson DJ. 2009 Pandemic influenza A (H1N1) in pregnancy: a
systematic review of the literature. Am J Obstet Gynecol. 2011 In press, corrected proof.
7. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines:
recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR.
2009; 58(RR-8):1–52. [PubMed: 19644442]
8. Ahluwalia IB, Jamieson DJ, D’Angelo DV, et al. Seasonal influenza and 2009 H1N1 influenza
vaccination coverage among pregnant women--10 states, 2009-10 influenza season. Morbidity and
Mortality Weekly Report. 2010; 59(47):1541–5. [PubMed: 21124293]
9. Ding H, Santibanez TA, Jamieson DJ, et al. Influenza vaccination coverage among pregnant
women-National 2009 H1N1 Flu Survey (NHFS). American Journal of Obstetrics and Gynecology.
2011; 204(6, Supplement 1):S96–S106. [PubMed: 21640233]
10. Sumaya CV, Gibbs RS. Immunization of Pregnant Women with Influenza A/New Jersey/76 Virus
Vaccine: Reactogenicity and Immunogenicity in Mother and Infant. J Infect Dis. 1979; 140(2):
141–6. [PubMed: 479636]
11. Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glazen WP. Maternal
Immunization with Influenza or Tetanus Toxoid Vaccine for Passive Antibody Protection in
Young Infants. J Infect Dis. 1993; 168(3):647–56. [PubMed: 8354906]
12. Steinhoff MC, Omer SB, Roy E, et al. Influenza Immunization in Pregnancy - Antibody Responses
in Mothers and Infants. N Engl J Med. 2010; 362(17):1644–46. [PubMed: 20427817]
13. Yamaguchi K, Hisano M, Isojima S, et al. Relationship of Th1/Th2 cell balance with the immune
response to influenza vaccine during pregnancy. Journal of Medical Virology. 2009; 81(11):1923–
8. [PubMed: 19774681]
14. Jackson LA, Patel SM, Swamy GK, et al. Immunogenicity of an Inactivated Monovalent 2009
H1N1 Influenza Vaccine in Pregnant Women. J Infect Dis. 2011; 204(6):854–63. [PubMed:
21849282]
15. Pandemic influenza A (H1N1) 2009 virus vaccine - conclusions and recommendations from the
October 2009 meeting of the immunization Strategic Advisory Group of Experts. Weekly
Epidemiological Record. 2009; 84(49):505–8. [PubMed: 19960623]
16. United States Food and Drug Administration, Guidance for Industry. Clinical Data Needed to
Support the Licensure of Seasonal Inactivated Influenza Vaccines. Available at
http://www.fda.gov/cber/guidelines.htm
17. Jackson L, Gaglani MJ, Keyserling HL. Safety, efficacy, and immunogenicity of an inactivated
influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza
seasons. BMC Infectious Diseases. 2010; 10(1):71. [PubMed: 20236548]
18. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009
Influenza. Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection. N Engl J Med.
2010; 362:1708–19. [PubMed: 20445182]
Sperling et al. Page 7













19. Weber DJ. Obesity as a Predictor of Poor Antibody Response to Hepatitis B Plasma Vaccine.
JAMA. 1985; 254(22):3187–9. [PubMed: 2933532]
20. Schäffler A, Schölmerich J. Innate immunity and adipose tissue biology. Trends in Immunology.
2010; 31(6):228–35. [PubMed: 20434953]
21. Zuckerman JN. The importance of injecting vaccines into muscle. BMJ. 2000; 321(7271):1237–8.
[PubMed: 11082069]
22. Braden CR. Listeriosis. Pediatric Infectious Disease Journal. 2003; 22(8):745–6. [PubMed:
12913780]
23. Shulman CE, Dorman EK. Importance and prevention of malaria in pregnancy. Transactions of the
Royal Society of Tropical Medicine and Hygiene. 2003; 97(1):30–5. [PubMed: 12886801]
24. Harger JH, Ernest JM, Thurnau GR, et al. Risk Factors and Outcome of Varicella Zoster Virus
Pneumonia in Pregnant Women. J Infect Dis. 2002; 185(4):422–7. [PubMed: 11865393]
25. Medina KG, Smithson, Kincade P. Suppression of B lymphopoiesis during normal pregnancy. J
Exp Med. 1993; 178(5):1507–15. [PubMed: 8228804]
26. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell
apoptosis and activation. J Clin Invest. 2002; 109(12):1625–33. [PubMed: 12070310]
27. Mai T, Zan H, Zhang J, Hawkins JS, Xu Z, Casali P. Estrogen Receptors Bind to and Activate the
HOXC4/HoxC4 Promoter to Potentiate HoxC4-mediated Activation-induced Cytosine Deaminase
Induction, Immunoglobulin Class Switch DNA Recombination, and Somatic Hypermutation.
Journal of Biological Chemistry. 2010; 285(48):37797–37810. [PubMed: 20855884]
28. Stavnezer J. Immunoglobulin class switching. Current Opinion in Immunology. 1996; 8(2):199–
205. [PubMed: 8725943]
29. Kraus TA, Sperling RS, Engel SM, et al. Peripheral Blood Cytokine Profiling During Pregnancy
and Post-partum Periods. American Journal of Reproductive Immunology. 2010; 64(6):411–26.
[PubMed: 20712812]
30. Pentšuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: New
insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Research Part
B: Developmental and Reproductive Toxicology. 2009; 86(4):328–44.
Sperling et al. Page 8














Seroprotection rates for Influenza A(H3N2 strains).
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Seroprotection rates for Influenza A (H1N1 strains).
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Table 4
Multivariable Model*




Younger than23 192 90 63.5 ref
23-29 179 86 63.7 1.06 (0.62-1.78)
30 or older 136 63 53.7 0.68 (0.38, 1.21)
Education (p=.12)
Less than high school 162 75 57.4 0.89 (.53-1.52)
High school 97 46 73.2 1.66 (.93-3.0)
Post-high school 248 118 58.5 ref
Obese (p=.16)
Nonobese 371 173 64.4 ref
Obese 136 66 51.5 0.68 (0.41-1.14)
Baseline hemagglutinin inhibition titer (p<.001)
0-20 354 204 69.8 ref
40 85 71 57.7 0.42 (.23-.74)
80 or higher 68 50 19.1 0.07 (0.03, 0.16)
Self-reported receipt of influenza vaccine in the
prior year (p=.03)
Yes 153 71 48.4 0.51 (.30-.85)
No 321 154 66.7 ref
Uncertain 33 14 63.6 1.32 (.45-3.84)
Vaccine strain by year (p<.001)
2006/2007 A/New Caledonia/20/99 35 62.9
2006/2007 A/Wisconsin/67/2005 35 37.1
2007/2008 A/Wisconsin/67/2005 50 64
2007/2008 A/Solomon Islands/03/2006 50 78
2008/2009 A/Brisbane 10/2007 68 64.7
2009/2010 A/Brisbane 10/2007 75 56
2008/2009 A/ Brisbane 59/2007 67 58.2
2009/2010 A/ Brisbane 59/2007 76 61.8
2009 Pandemic A/California 04/2009 51 60.8
*
P-values are for each term, adjusting for all other terms in the model.
Obstet Gynecol. Author manuscript; available in PMC 2013 March 01.
